PKI-166

Products

Catalog No.: PC0153

Size: 5 mg, 10 mg, 25 mg,50 mg, 100 mg, 200 mg, 500 mg

PKI-166 is a potent, selective and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC₅₀ of 0.7 nM.

Molecular Weight	330.38
Formula	C20H18N4O
CAS No.	187724-61-4
Appearance	Solid
Color	Off-white to light yellow
SMILES	OC1=CC=C(C2=CC3=C(N=CN=C3N2)N[C@@H](C4=CC=CC=C4)C)C=C1
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
*In Vitro*	Pretreatment with PKI-166 (0-0.5 μM; 1 hour) inhibits EGFR autophosphorylation in human pancreatic cancer cells. PKI-166 (0.03μ M; 6 days) enhanced the cytotoxicity mediated by gemcitabine.
*In Vivo*	PKI-166 (100 mg/kg; p.o.; daily; day 7-day 35 after xenograft) inhibits of pancreatic cancer growth.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.